Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
出版年份 2021 全文链接
标题
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-04-29
DOI
10.3389/fphar.2021.614811
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
- (2020) Naielly Rodrigues da Silva et al. PHARMACOLOGICAL RESEARCH
- From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
- (2020) Tommaso Cassano et al. Frontiers in Pharmacology
- Relationship of negative symptom severity with cognitive symptoms and functioning in subjects at ultra‐high risk for psychosis
- (2020) Alp Üçok et al. Early Intervention in Psychiatry
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor
- (2018) Annalaura Sabatucci et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
- (2018) F. Markus Leweke et al. CNS DRUGS
- Intellectual and cognitive profiles in patients affected by schizophrenia
- (2018) Margherita Bechi et al. Journal of Neuropsychology
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings
- (2018) Md. A. Islam et al. ACTA PSYCHIATRICA SCANDINAVICA
- Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
- (2018) Andreza B. Sonego et al. BRAIN BEHAVIOR AND IMMUNITY
- Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis
- (2018) Max Lam et al. JAMA Psychiatry
- Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis
- (2018) Sagnik Bhattacharyya et al. JAMA Psychiatry
- Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol
- (2018) Christian Makiol et al. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
- Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set
- (2017) Guillaume Fond et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Speech graph analysis of verbal fluency tests distinguish between patients with schizophrenia and healthy controls
- (2017) A. Turek et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cognitive clusters in first-episode psychosis: Overlap with healthy controls and relationship to concurrent and prospective symptoms and functioning.
- (2017) Jacqueline Uren et al. NEUROPSYCHOLOGY
- Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
- (2017) Marco Aurélio Mori et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Placebo Response and Practice Effects in Schizophrenia Cognition Trials
- (2017) Richard S. E. Keefe et al. JAMA Psychiatry
- Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
- (2016) Andreza B. Sonego et al. BEHAVIOURAL BRAIN RESEARCH
- Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors
- (2016) William H Hind et al. BRITISH JOURNAL OF PHARMACOLOGY
- Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo
- (2016) Lone Baandrup et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- The dopamine D3 receptor, a quarter century later
- (2016) Pierre Sokoloff et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study
- (2016) Wing Chung Chang et al. SCHIZOPHRENIA RESEARCH
- Association of Neurocognition With Transition to Psychosis
- (2016) Larry J. Seidman et al. JAMA Psychiatry
- Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
- (2016) Cathrin Rohleder et al. Frontiers in Pharmacology
- Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
- (2015) R B Laprairie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- (2015) Matthew W. Elmes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia
- (2014) G. Fervaha et al. ACTA PSYCHIATRICA SCANDINAVICA
- Neurocognitive Decrements are Present in Intellectually Superior Schizophrenia
- (2014) Anja Vaskinn et al. Frontiers in Psychiatry
- Anandamide Dysfunction in Prodromal and Established Psychosis
- (2012) F. Markus Leweke CURRENT PHARMACEUTICAL DESIGN
- Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data
- (2012) Hitoshi Sakurai et al. SCHIZOPHRENIA BULLETIN
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
- (2011) EM Rock et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
- (2011) Giuseppe Esposito et al. PLoS One
- Effects of cannabinoids and cannabinoid-enrichedCannabisextracts on TRP channels and endocannabinoid metabolic enzymes
- (2010) Luciano De Petrocellis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies
- (2010) Terry E Goldberg et al. NEUROPSYCHOPHARMACOLOGY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Neurocognition in first-episode schizophrenia: A meta-analytic review.
- (2009) Raquelle I. Mesholam-Gately et al. NEUROPSYCHOLOGY
- Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
- (2008) Somaia Mohamed et al. AMERICAN JOURNAL OF PSYCHIATRY
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
- (2008) Keith H. Nuechterlein et al. AMERICAN JOURNAL OF PSYCHIATRY
- Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?
- (2008) Herbert Y. Meltzer et al. BEHAVIOURAL BRAIN RESEARCH
- Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone
- (2008) Yu-Ting Wang et al. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
- Cannabidiol for the treatment of psychosis in Parkinson’s disease
- (2008) AW Zuardi et al. JOURNAL OF PSYCHOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More